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Abstract
Background & Aims: We tested the putative association of the rs58542926 variant of TM6SF2, a recently described genetic
determinant of nonalcoholic fatty liver disease, with steatosis and fibrosis in genotype 1(G1) chronic hepatitis C(CHC)
patients. Methods: A total of 694 consecutively biopsied Caucasian G1 CHC patients were genotyped for TM6SF2
rs58542926, IL28B rs12979860 and PNPLA3 rs738409. Steatosis was classified as absent (<5%), mild-moderate(5–29%)
and severe(≥30%), Fibrosis was considered severe if=F3-F4. Results: Carriers of TM6SF2 rs58542926 (6.3% of patients)
exhibited lower serum levels of cholesterol (P = 0.04) and triglycerides (P = 0.01), but a similar distribution of steatosis sever-
ity (P = 0.63), compared to noncarriers. Prevalence and severity of steatosis were reduced in IL28B C allele carriers
(P = 0.005) and elevated in PNPLA3 G allele carriers (P < 0.001). After adjustment for age, gender, body mass index and
homoeostasis model assessment score, steatosis severity was independently associated with IL28B rs12979860 (odds ratio
[OR] 0.69, 95% confidence interval [CI] 0.55–0.86, P = 0.001) and PNPLA3 rs738409 (OR 1.84, 95% CI 1.46–2.83,
P < 0.001), but not TM6SF2 rs58542926 (OR 1.48, 95% CI 0.82–2.69, P = 0.19). Variants of TM6SF2 (30.9% vs. 25%,
P = 0.40), IL28B and PNPLA3 were not directly associated with fibrosis severity, although variants of IL28B and PNPLA3 pro-
moted steatosis (OR 1.36, 95% CI 1.06–1.75, P = 0.01) that in turn is associated with severe fibrosis. Conclusions: In G1
CHC patients, TM6SF2 rs58542926 does not affect the histological severity of liver damage. However, IL28B rs12979860
and PNPLA3 rs738409 modify steatosis.
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The estimated global prevalence of hepatitis C virus
(HCV) infection is 2.2%, corresponding to about 130
million HCV-positive persons worldwide, most of
whom are chronically infected (1). HCV is one of the
main causes of cirrhosis, hepatocellular carcinoma and
liver transplantation in Western countries. The recent
development of interferon-free therapeutic regimens to
treat HCV would allow for the eradication of infection
in more than 90% of treated patients and a strong
improvement in the natural history of their liver disease
(2). However, the impossibility of treating all infected
patients (because of cost) and the presence of numerous
cofactors that accelerate the progression and complica-
tions of HCV-associated liver disease have prompted
clinical research to understand the modifiers of liver
damage.
In this complex landscape, hepatic steatosis and some
of its genetic determinants exert key roles as modifiers
of liver disease severity in patients with genotype 1 (G1)
chronic hepatitis C (CHC). Specifically, steatosis has
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been associated with an increased severity of liver fibro-
sis (3). It also has emerged as a predictor of fibrosis pro-
gression (4) and hepatocellular carcinoma occurrence
(5). Variants of two genes, PNPLA3 and IL28B, have
been reported to affect the prevalence and severity of
steatosis, the severity of fibrosis and the prognosis of
liver disease in patients with CHC (6–16). Specifically,
the PNPLA3 rs738409 and IL28B rs12979860 variants
are the strongest known genetic risk factors for occur-
rence of nonalcoholic fatty liver disease (NAFLD) (6)
and for response to interferon/ribavirin therapy in CHC
(7) respectively.
A recent exome-wide study identified the rs58542926
variant of TM6SF2, a gene that modulates lipid export
from the liver, as a new genetic determinant of NAFLD
(17). This variant is a nonsynonymous C>T polymor-
phism. Recent studies by others and us have demon-
strated that this variant increases the risk that NAFLD
patients will develop liver fibrosis and steatohepatitis
(18–20). Only two studies have examined the effects of
the TMS6SF2 variant in CHC patients (21,22). How-
ever, the inclusion of CHC patients with different HCV
genotypes complicates the interpretation of these
studies. Therefore, a large study of this variant in CHC
patients with a single HCV genotype has been neces-
sary. The aim of this study was to assess the putative
association between the TM6SF2 polymorphism and
histological steatosis, as well as the impact on the sever-
ity of liver fibrosis in a large cohort of G1 CHC
patients.
Patients and methods
This study cohort comprised 694 CHC patients who
were consecutively enrolled at the Gastrointestinal and
Liver Unit of the University Hospital Palermo, Italy.
The following inclusion criteria were applied: (a) diag-
nosis of G1 CHC based on HCV serology and viral
RNA, (b) histological diagnosis of CHC by liver biopsy,
(c) self-reported alcohol consumption of less than 20 g/
day in the last 12 months, as evaluated by a question-
naire and (d) availability of DNA for genotyping.
Patients were excluded from this study if they were
co-infected with either the hepatitis B virus or HIV.
This study was carried out in accordance with the
principles of the Helsinki Declaration and its appen-
dices, as well as with local and national laws. Approval
was obtained from the AOUP Paolo Giaccone of Paler-
mo’s Internal Review Board and its Ethics Committee.
Written informed consent was obtained from all
patients.
Clinical and laboratory evaluation
Clinical and anthropometric data were collected at the
time of liver biopsy. Patients with a body mass index
(BMI) of 30 kg/m2 or greater were classified as obese.
Impaired glucose tolerance and type 2 diabetes mellitus
(T2DM) were diagnosed on the basis of the revised cri-
teria of the American Diabetes Association (fasting
blood glucose of 100–125.9 mg/dl for impaired glucose
tolerance or ≥126 mg/dl for T2DM) (23). In patients
with a previous diagnosis of T2DM, current therapy
with insulin or oral hypoglycaemic agents was recorded.
A 12-h overnight fasting blood sample was drawn at
the time of biopsy to determine the serum levels of ALT,
total cholesterol (TC), triglycerides (TG), plasma glu-
cose, insulin and platelet count. Insulin resistance (IR)
was determined according to the homoeostasis model
assessment (HOMA) method (24): Insulin resistance
(HOMA-IR) = Fasting insulin (lU/ml) 9 Fasting
blood glucose (mmol/L)/22.5.
Genotyping
DNA was extracted from peripheral blood collected at
the time of enrolment in all patients. Genotyping for
TM6SF2 (rs58542926), PNPLA3 (rs738409) and IL28B
(rs12979860) was carried out by using the TaqMan SNP
genotyping allelic discrimination method (Applied
Biosystems, Foster City, CA, USA). Genotyping calls
were made by using the SDS software package (v.1.3.0,
ABI Prism 7500, Foster City, CA, USA). Genotyping was
conducted in a blinded fashion relative to patient char-
acteristics.
Histopathology
A liver biopsy was performed for all patients. Liver his-
tology was used to determine the extents of steatosis,
hepatic necroinflammation and fibrosis. Steatosis was
graded as absent (<5%), mild-moderate (5–29%) or
severe (≥30%). Liver fibrosis and necroinflammatory
activity were classified according to the Scheuer score
(25).
Statistical analysis
Our study had a power of more than 80% for detecting
an odds ratio (OR) of 1.5 for steatosis for the TM6SF2
Key points
• The TM6SF2 rs58542926 gene variant has been
associated with the presence and histological severity
of nonalcoholic fatty liver disease.
• Previously reported preliminary data in hepatitis C
virus-infected patients suggested that TM6SF2
rs58542926 modulates steatosis.
• In this study of the largest cohort of genotype 1
chronic hepatitis C patients, we found that the
TM6SF2 rs58542926 gene variant is not linked to the
presence or severity of fatty liver or fibrosis.
• We confirmed the association of variants of
PNPLA3 and IL28B in modifying steatosis.
Liver International (2016)
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 199
Petta et al. TM6SF2 in chronic hepatitis C
rs58542926 variant, with a significance of 5%. Continu-
ous variables were summarized as the mean ± SD, and
categorical variables as the frequency and percentage.
The t- and v2 tests were used where appropriate. Multi-
ple ordinal regressions were used to assess variables
associated with the severity of steatosis. Multiple logistic
regression models were used to assess the factors associ-
ated with severe fibrosis. ORs and 95% confidence inter-
vals (CIs) are reported.
As candidate risk factors, we used gender, age, BMI,
HOMA score, TM6SF2 rs58542926 genotype, PNPLA3
rs738409 genotype and IL28B rs12979860 genotype. In
the analysis, the TM6SF2 E172K variant was coded in a
dominant genetic model because of its relatively low
allele frequency (19,20). The PNPLA3 and IL28B vari-
ants were coded in an additive model. Analyses were
performed by using the SPSS software package.
Results
Patient features and histology
Baseline characteristics of the 694 patients are shown in
Table S1. The mean age was 53 years, and 54% of
patients were male. Obesity and T2DM each were
observed in about 13% of patients. Mean TC and TG
levels were within the normal range. The mean HOMA
value was 3.37. One-third of patients had severe fibrosis.
Steatosis was observed in about half of cases, and 17%
had high-grade steatosis.
Distributions of the IL28B rs12979860 and PNPLA3
rs738409 genotypes are reported in Table S1. For the
TM6SF2 rs58542926 variant, 93.7% of patients were
homozygous for the C allele, and 6.3% of cases carried
the T variant. Only one patient was homozygous for the
T allele. Genetic frequencies were in Hardy–Weinberg
equilibrium. In our cohort, the metabolic profile dif-
fered according to the TM6SF2 genotype (Table 1).
Patients carrying the rs58542926 variant were character-
ized by lower serum levels of TC (P = 0.04) and TG
(P = 0.01) compared to noncarriers.
Associations of gene variants with steatosis severity in G1
CHC patients
Patients carrying the TM6SF2 rs58542926 variant had a
similar distribution of steatosis severity as noncarriers.
Percentages of patients with absent, mild-moderate and
severe steatosis were 54.8%, 28.8% and 16.4%, respec-
tively, in carriers compared to 47.7%, 31.8% and 20.5%,
respectively, in noncarriers (P = 0.63, Fig. 1A). Preva-
lence and severity of steatosis were lower in patients car-
rying the IL28B C allele (P = 0.005, Fig. 1B) and
elevated in those carrying the PNPLA3 G allele
(P < 0.001, Fig. 1C) compared to the corresponding
noncarriers.
A multivariate ordinal regression analysis adjusted
for age, gender, BMI and HOMA score showed that
the aforementioned variants of IL28B (OR 0.69, 95%
CI 0.55–0.86, P = 0.001) and PNPLA3 (OR 1.84, 95%
CI 1.46–2.83, P < 0.001), but not of TM6SF2 (OR
1.48, 95% CI 0.82–2.69, P = 0.19), were independently
associated with the severity of steatosis (Table 2).
Severity of steatosis was also associated with age (OR
1.02, 95% CI 1.01–1.03, P < 0.001), BMI (OR 1.13,
95% CI 1.08–1.18, P < 0.001) and HOMA score (OR
1.08, 95% CI 1.01–1.16, P = 0.01). When T2DM was
included in the model instead of HOMA, similar
results were observed. The lack of association between
the TM6SF2 variant and steatosis severity, as well as
the independent link between the IL28B and PNPLA3
variants and steatosis severity, were further confirmed
in subgroups of nondiabetic or nonobese patients (data
not shown).
When we considered severe steatosis (≥30%) as a
dichotomous variable, BMI (OR 1.08, 95% CI 1.02–
1.14, P = 0.007), HOMA score (OR 1.13, 95% CI
1.02–1.25, P = 0.01) and the PNPLA3 variant (OR 1.98,
95% CI 1.38–2.84, P < 0.001), but not the TM6SF2
variant (OR 1.49, 95% CI 0.60–3.73, P = 0.38), were
Table 1. Characteristics of 694 patients with genotype 1 chronic
hepatitis C, according to TM6FS2 rs58542926 genotype
Variable
TM6SF2
CC
n = 650 (93.6)
TM6SF2
TC/TT
n = 44 (6.4)
P
value
Age (yrs) 53.7 ± 11.9 52.9 ± 11.7 0.65
Male gender (%) 53.8 61.3 0.33
Body mass
index (kg/m2)
26.6 ± 3.6 25.7 ± 2.9 0.21
Body mass index
≥30 kg/m2 (%)
13.2 6.8 0.21
Alaninoaminotransferase
(IU)
88.1 ± 73.8 76.5 ± 51.2 0.30
Platelets (103/mmc) 204.5 ± 83.1 212.2 ± 65.5 0.54
Cholesterol (mg/dl) 174.0 ± 34.0 163.6 ± 34.9 0.04
Triglycerides (mg/dl) 95.8 ± 47.0 77.9 ± 31.6 0.01
Blood glucose
(mg/dl)
96.1 ± 27.0 93.7 ± 19.3 0.56
Insulin (lU/ml) 13.8 ± 9.4 11.8 ± 7.6 0.30
HOMA 3.39 ± 2.25 3.15 ± 1.78 0.49
Type 2 diabetes (%) 13.0 9.1 0.44
IL28B TT/TC/CC 16.8/54.0/29.2 22.7/54.6/22.7 0.48
PNPLA3 CC/CG/GG 54.3/38.2/7.5 59.1/29.5/11.4 0.41
HCVRNA (LOG) 5.9 ± 0.6 5.8 ± 0.6 0.45
Histology at biopsy
Steatosis grade (%)
Absent/mild-
moderate/severe
54.8/28.8/16.4 47.7/31.8/20.5 0.63
Necroinflammatory
activity (%)
Severe 43.8 38.6 0.50
Fibrosis (%)
Absent/mild-
moderate/severe
30.9 25.0 0.40
yrs, years; IU, international units; HOMA, homoeostasis model assess-
ment. Data are given as mean ± SD or as %.
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independent risk factors by multivariate logistic
regression analysis. Similarly, steatosis as continuous
variable was independently associated with older age
(P = 0.04), higher BMI (P < 0.001), higher HOMA
score (P = 0.001), lack of the IL28B C allele (P = 0.01)
and presence of the PNPLA3 G allele (P < 0.001), but
not with presence of the TM6SF2 T allele (P = 0.07), by
multivariate linear regression analysis.
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Fig. 1. Severity of steatosis according to TM6SF2 (A), IL28B (B) and PNPLA3 (C) genotypes.
Table 2. Factors associated with severity of steatosis in 694 patients with genotype 1 chronic hepatitis C
Variable
Simple ordinal regression Multiple ordinal regression
OR (95% CI) P value OR (95% CI) P value
Age (yrs) 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) <0.001
Female gender 1.12 (0.84–1.50) 0.41 1.04 (0.76–1.41) 0.79
Body mass index (kg/m2) 1.14 (1.09–1.19) <0.001 1.13 (1.08–1.18) <0.001
HOMA 1.16 (1.09–1.25) <0.001 1.08 (1.01–1.16) 0.01
TM6SF2
CC/CT/TT
1.32 (0.74–2.34) 0.34 1.48 (0.82–2.69) 0.19
IL28B
TT/TC/CC
0.66 (0.53–0.82) <0.001 0.69 (0.55–0.86) 0.001
PNPLA3
CC/CG/GG
1.74 (1.38–2.17) <0.001 1.84 (1.46–2.33) <0.001
yrs, years; IU, international units; HOMA, homoeostasis model assessment. Data are given as mean ± SD or as %.
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Association of gene variants and steatosis severity with
fibrosis severity in CHC patients
The prevalence of F3-F4 fibrosis was similar in patients
with the TM6SF2 CC genotype compared to the CT
genotype (30.9% vs. 25%, P = 0.40; Fig. 2). Simple
logistic regression revealed that older age, higher
HOMA score, severity of steatosis and severe necroin-
flammatory activity were associated with severe fibrosis
(P < 0.01, Table 3). Multiple logistic regression con-
firmed that age (OR 1.04, 95% CI 1.02–1.06,
P < 0.001), HOMA score (OR 1.23, 95% CI 1.12–1.35,
P < 0.001), severity of steatosis (OR 1.36, 95% CI
1.06–1.75, P = 0.01) and severe necroinflammatory
activity (OR 3.55, 95% CI 2.46–5.12, P < 0.001), but
not the TM6SF2 variant (OR 0.75, 95% CI 0.34–1.63,
P = 0.47), the IL28B variant (OR 0.98, 95% CI
0.74–1.29, P = 0.90), or the PNPLA3 variant (OR 0.99,
95% CI 0.74–1.32, P = 0.96), were independent predic-
tors of severe fibrosis (Table 3). None of the gene vari-
ants remained associated with severe fibrosis when
histological variables were removed from the model.
Discussion
We demonstrated that the TM6SF2 rs58542926 variant
does not affect the severity of liver damage in terms of
steatosis or fibrosis, using a large cohort of Caucasian
patients with G1 CHC and a low prevalence of obesity.
Furthermore, we confirmed the key roles of IL28B and
PNPLA3 gene variants as steatosis modifiers.
Several lines of evidence in CHC have demonstrated
that hepatic steatosis and some of its genetic determi-
nants (e.g. PNPLA3 and IL28B gene variants) affect the
severity of liver damage and the liver-related prognosis
of patients (3,15). Considering the recent evidence that
TM6SF2 rs58542926 promotes steatosis and liver dam-
age in NAFLD (17–20), we examined its potential role
in CHC. Our findings confirmed the low prevalence of
the TM6SF2 variant in a population with G1 CHC, as
well as the association of this gene variant with lower
TC and TG levels (17,19,20,26). We further confirmed
the lack of an association between the TM6SF2 genotype
and IR, as was reported in an elegant study by Zhou and
colleagues (27). Unexpectedly, we found no association
between the TM6SF2 variant and the presence or sever-
ity of steatosis in G1 CHC patients after adjusting for
genetic and metabolic confounders. This result was
further confirmed in subgroups of nondiabetic patients
and nonobese patients, as well as by sorting steatosis at
different thresholds.
The strength of our study lies in the large number of
patients enrolled. To date, this study uses the largest
cohort of G1 CHC patients to investigate the associa-
tion between the TM6SF2 variant and steatosis in a
clinical setting. Our results are not inconsistent with
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Fig. 2. Prevalence of F3-F4 fibrosis according to the TM6SF2
genotype.
Table 3. Factors associated with severe fibrosis in 694 patients with genotype 1 chronic hepatitis C
Variable
Simple logistic regression Multiple logistic regression
OR (95% CI) P value OR (95% CI) P value
Age (yrs) 1.04 (1.03–1.06) <0.001 1.04 (1.02–1.06) <0.001
Female gender 0.76 (0.55–1.05) 0.10 0.70 (0.48–1.01) 0.06
Body mass index (kg/m2) 1.00 (0.96–1.05) 0.76 0.94 (0.89–1.01) 0.06
HOMA 1.23 (1.13–1.34) <0.001 1.23 (1.12–1.35) <0.001
TM6SF2
CC/CT/TT
0.74 (0.36–1.50) 0.41 0.75 (0.34–1.63) 0.47
IL28B
TT/TC/CC
0.94 (0.74–1.20) 0.64 0.98 (0.74–1.29) 0.90
PNPLA3
CC/CG/GG
1.02 (0.79–1.31) 0.86 0.99 (0.74–1.32) 0.96
Severity of steatosis 1.60 (1.30–1.98) <0.001 1.36 (1.06–1.75) 0.01
Severe necroinflammatory activity 3.95 (2.81–5.57) <0.001 3.55 (2.46–5.12) <0.001
yrs, years; IU, international units; HOMA, homoeostasis model assessment. Data are given as mean ± SD or as %.
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the exome-wide study by Kozlitina et al. (17).
Although their study was population-based, we looked
at the TM6SF2 gene variant as a risk factor for steatosis
in a population of CHC patients, who have a higher
incidence of steatosis compared to the general popula-
tion (28).
On the other hand, our data do not agree with data
from two recent studies on CHC (21,22). Coppola and
colleagues (21) found an association between steatosis
and the TM6SF2 variant in a small cohort (n = 148) of
CHC patients with different HCV genotypes. Similarly,
Milano and colleagues (22) identified a link between the
TM6SF2 variant and steatosis in 815 CHC patients,
confirming this association in the subgroup of 451 G1
patients only. Several factors may account for the
inconsistent results between studies, including the low
number of patients evaluated in proportion to the low
prevalence of the TM6SF2 variant (21), the inclusion of
patients with different CHC genotypes (21,22), as well
as differences in histological methods (21,22), mean
BMI (22) and the percentage of patients with moderate
alcohol intake (22). Our study results confirm the
modulation of steatosis and its severity by variants in
the PNPLA3 and IL28B genes in patients with CHC
(8,9,11,12).
The lack of an association between the TM6SF2
variant and steatosis in CHC may be explained by con-
sidering the mechanisms leading to steatosis in CHC,
and the mechanisms by which the TM6SF2 variant
promotes liver fat accumulation. In patients with CHC,
steatosis is a prevalent histological finding related to
metabolic and viral factors, including induction of IR
(especially for G1 patients) and impairment of lipid
export from the liver (especially for, but not exclusive
to, G3 patients) (28). In experimental models, silencing
TM6SF2 reduces the secretion of very low density
lipoproteins and causes a predisposition to fatty liver
development (17,26). Therefore, although the TM6SF2
variant does not interfere with IR (27), both HCV
infection and TM6SF2 promote steatosis by affecting
lipid export from the liver, although by different
pathways. Accordingly, we might hypothesize that the
steatogenic effect of the TM6SF2 variant could be
clinically less relevant in CHC patients.
We did not find any association between the TM6SF2
variant and liver fibrosis, as was observed in NAFLD
patients (18–20) and CHC patients (22). In NAFLD, the
link between fibrosis and the TM6SF2 variant is medi-
ated by steatohepatitis. Thus, the lack of an effect of the
TM6SF2 variant on liver fat accumulation in our CHC
cohort could explain the absence of a link with the
severity of fibrosis. In our population, PNPLA3 and
IL28B gene variants were not directly associated with
F3-F4 fibrosis, although their effects were mediated by
steatosis induction. Further studies are necessary to
establish how the HCV genotype and other clinical char-
acteristics impact the effect of the TM6SF2 variant on
steatosis and liver damage in CHC.
From a clinical perspective, our data confirm the
roles of the PNPLA3 and IL28B gene variants, but not
the TM6SF2 variant, as major disease-modifying factors
in CHC that promote histological steatosis, which con-
tributes to the progression of liver disease. If confirmed
in other studies performed in other geographical and
clinical settings, this relationship would suggest that
genotyping of PNPLA3 and IL28B, but not TM6SF2,
should be undertaken in CHC for risk stratification and
personalized disease management, with more intensive
follow-up of patients with the variant genotype, both
before and after viral eradication.
The main limitation of this study lies in the poten-
tially limited external validity of the results for different
populations and settings. Thus, replicating our results is
important. Lack of data on body fat distribution, serum
levels of adipocytokines and other polymorphisms that
could conceivably confound the data may have also
affected the results. In conclusion, we found that in a
large cohort of G1 CHC patients with a low prevalence
of obesity, the TM6SF2 rs58542926 variant does not
affect the severity of liver damage in terms of steatosis
or fibrosis. However, we did confirm the key roles of
IL28B and PNPLA3 gene variants as steatosis modifiers.
These data, if further validated, could be useful in
managing patients before and after therapy.
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